Thrombophilia Treatment Market Share

APAC Market Statistics

On the basis of geographical analysis, the global thrombophilia treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is set to account for largest revenue share by 2036, owing to growing investments for improving healthcare infrastructure, and larger patient pool in the region.

North America Market Analysis

Moreover, the market in North America is expected to occupy the largest share during the forecast period ascribing to the rising demand for progressive treatment options, and early adoption of technologies, especially in the United States. In addition, increasing geriatric population, and growing collaboration of domestic and international companies for awareness campaigns are also predicted to boost the region’s market growth in the coming years. As per the data given by Rural Health Information Hub, there are more than 46 million adults aged 65 years or older living in the United States as of 2019. By 2050, this number is anticipated to reach almost 90 million.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of thrombophilia treatment is estimated at USD 17.65 billion.

Thrombophilia Treatment Market size was over USD 16.74 billion in 2023 and is anticipated to reach USD 39.37 billion by 2036, growing at around 6.8% CAGR during the forecast period i.e., between 2024-2036. The market growth is driven by growing burden of obesity, and increasing prevalence of cardiovascular and trauma cases worldwide.

Asia Pacific industry is set to account for largest revenue share by 2036, owing to growing investments for improving healthcare infrastructure, and larger patient pool in the region.

The major players in the market are Sanofi SA, Pfizer, Inc., Aspen Pharmacare Holdings Limited, Boehringer Ingelheim GmbH, and others.

Thrombophilia Treatment Market Share